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The effect of immunosuppressive drugs on the generation of T follicular helper (Tfh) cells,
specialized in supporting B-cell differentiation, is largely unknown. We examined whether
the calcineurin inhibitor tacrolimus (TAC) and the mammalian target of rapamycin (mtor)
inhibitor sirolimus (SRL) inhibit Tfh cell differentiation, and affect subsequent B-cell
functions. Isolated naive T cells were polarized into Tfh-like cells in the presence of TAC
or SRL. To demonstrate their functionality, we co-cultured these cells with isolated B cells
in the presence of alloantigen and studied the activation and differentiation of these B
cells. Tfh-like cells were deﬁned as CD4þCXCR5þ T cells, expressing immunoinhibitory
programmed death protein 1 (pd1) and inducible T-cell costimulator (icos). We found that
TAC and SRL signiﬁcantly inhibited Tfh-like cell differentiation. Therapeutic concentra-
tions of TAC and SRL reduced the percentage of pd1þ and icosþ Tfh cells compared to
controls. In addition, T cells grown in the presence of TAC or SRL expressed less IL-21
and provided less B-cell help. TAC and SRL both inhibited Tfh-dependent alloantigen-
activated B-cell proliferation and differentiation into plasma cells and transitional B cells.
In conclusion, TAC and SRL inhibited the differentiation of naive T cells into functional
Tfh-like cells, a ﬁnding that can be extrapolated to immunosuppressive regimens in
transplant patients.The ﬁrst 2 authors contributed equally to this work.
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E-mail: r.kraaijeveld@erasmusmc.nlWORLDWIDE, over 100,000 transplantations areperformed each year, with numbers rising annually.
In spite of this increase, the number of patients requiring a
transplant is rising even more rapidly and exceeds the
number of organs available for transplantation. Although
the lifespan of a transplanted organ has increased over the
last decade due to the introduction of new pharmaceutical
agents and improved diagnostics, the loss of organ trans-
plants over 10 years is still at 30%, of which 30% to 50% is
caused by chronic humoral rejection (ie, antibody-mediated
rejection, or ABMR) [1,2]. Current strategies to target
ABMR are generally not used as maintenance therapy and
have several side effects. Improved treatment strategies are
therefore needed to more speciﬁcally prevent and treat this
type of rejection [3].Authors. Published by Elsevier Inc. This is an open
le under the CC BY-NC-ND license (http://
mons.org/licenses/by-nc-nd/4.0/).
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ion Proceedings, XX, 1e11 (2019)After transplantation, a graft can not only be rejected
due to humoral immunity, but also cellular immunity (ie, T
cellemediated rejection, or TCMR). And although the
names suggest that these rejections are mediated by only
antibodies or T cells, the opposite is quite true. Previous0041-1345/19
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Fig 1. Experimental setup. Flow
chart that represents the overall
setup of the performed
experiments.
2 KRAAIJEVELD, LI, YAN ET ALstudies reported that in TCMR, as well as ABMR, and
both inﬁltrating B cells and T cells, can be found [4].
Different T helper subsets, including T helper 1 (Th1), T
helper 2 (Th2), regulatory T (Treg) cells, and T follicular
helper (Tfh) cells fulﬁll different roles in transplant
alloreactivity. For example, whereas Th1 cells are mostly
mediators of TCMR, Tfh cells are important mediators of
B cellemediated humoral immunity [5,6]. Activation of
these Tfh cells consists of 3 signals: (1) the interaction of
T-cell receptors with HLA-presented allopeptide; (2)
costimulation molecules, such as pd1 and icos; and (3) the
cytokine interleukin (IL) 21. Peripheral blood
CD4þCXCR5þ T cells represent the circulating memory
compartment of Tfh-lineage cells [7]. Importantly, circu-
lating CD4þCXCR5þ T cells expressing high levels of the
coinhibitory molecule pd1 reﬂect active Tfh cell differen-
tiation in lymphoid tissues. This CD4þ T-cell subtype isFig 2. Upregulation of transcription fac-
tors. After stimulating CD4þ naive T help-
er cells for 5 days with anti-CD3/28
antibodies, goat antimouse antibodies,
and IL-12 and IL-21, we found an upre-
gulation of the transcription factors
bcl6, tbet, gata3, and foxp3. Expression
of rorgt was not detected in both condi-
tions and therefore not shown (n ¼ 5).
Note. Mann-Whitney testing was used.
*Indicates P < .05. yIndicates P < .01.specialized in supporting B-cell activation and differenti-
ation (plasma blasts and transitional B cells) [8e11]. In
organ transplantation, this can lead to the secretion of
donor-speciﬁc antibodies [6,10e12], resulting in ABMR in
patients with a transplant who are receiving lifelong
immunosuppression [12,13]. Tfh cells are thought to be
derived from naive T cells, and differentiation toward the
Tfh phenotype is most likely initiated by dendritic cell
interaction. This is primarily mediated by IL-6, IL-12, IL-
21, and transforming growth factor b [10e14]. These naive
T cells will then upregulate B-cell lymphoma 6 (bcl6)
protein, which is an important transcription factor for Tfh
cell differentiation. In contrast, IL-2 and IL-10 have been
described as negative regulators of Tfh differentiation.
These cytokines activate the transcription factor B
lymphocyte-induced maturation protein 1 (blimp1), which
inhibits bcl6 expression [15e17].
Fig 3. Representative FACS plots
showing the gating strategy to determine
the frequencyofTfh (CD4þCXCR5þPD1þhi
andCD4þCXCR5þicosþhi T cells). (A) Flow
cytometry plots of the frequency of
CD45ROþ memory CD4þ T cells,
CD4þCXCR5þ cells, CXCR5þ pd1þhi cells,
and CXCR5þicosþhi cells after 5-day cul-
ture of CD4þCD45RAþ naive T cells
without stimulation. (B) Flow cytometry
plots of the expression of CD45ROþmem-
ory cells, CD4þCXCR5þ cells, CXCR5þ
pd1þhi cells, andCXCR5þicosþhi cells after
5-day culture of CD4þCD45RAþ naive T
cells with the stimulation of anti-CD3/28
antibodies, goat antimouse antibody, IL-
21, and IL-12. FACS, ﬂuorescence-
activated cell sorting; Tfh, T follicular
helper.
TACROLIMUS AND SIROLIMUS INHIBIT TFH GENERATION 3After organ transplantation, patients must remain on
lifelong immunosuppression, such as tacrolimus (TAC) and
sirolimus (SRL), to prevent transplant rejection. TAC in-
hibits the calcineurin pathway, thereby blocking the tran-
scription of T-cell growth factors, such as IL-2 [18e20]. SRL
is a mammalian target of rapamycin (mtor) inhibitor that
inhibits multiple cellular processes, such as IL-2 mediatedT-cell proliferation [21]. These agents might affect Tfh as
well as other T helper subtype cell activity and subsequent
B-cell responses in different ways. This can be explained by
the fact that IL-2, a cytokine inhibited by TAC, antagonizes
Tfh cell differentiation [22]. TAC has been shown to pre-
vent B cellemediated humoral alloreactivity in patients with
transplant by inhibiting B-cell proliferation [23,24].
Fig 4. The differentiation of naive T helper cells into T follicular helper cells. The percentage of CXCR5þ within CD4þ T cells and the
percentage of CD45ROþ, CXCR5þ, icosþhi, and pd1þhi cells within CD4þCXCR5þ T cells are depicted, with and without stimulation,
proving that all CXCRþ CD4þ T cells generated are highly positive for these markers. Note. Data are presented as the median of the
percentage. icos, inducible T-cell costimulator; pd1, immunoinhibitory receptor programmed death 1.
4 KRAAIJEVELD, LI, YAN ET ALHowever, its effect on T celledependent antibody produc-
tion has been inconclusive [25,26]. In contrast, SRL affects
both T celledependent and T celleindependent B-cell pro-
liferation and antibody production, while also increasing B-
cell apoptosis [26].
In our previous clinical study in renal transplant re-
cipients, we found that the frequency of
CD4þCXCR5þpd1þhi Tfh cells was signiﬁcantly higher in
the TAC-treated group than in the SRL-treated cohort,
suggesting that SRL might suppress the generation of Tfh
cells more effectively than TAC in vivo [26]. It is unknown
whether this observation is the result of the combination of
immunosuppressive therapy given to transplant recipients.
This makes it difﬁcult, if not impossible, to draw conclusionsFig 5. Effect of TAC and SRL on bcl6/tbet ratio. This ﬁgure
shows the ratio of the relative mRNA expression levels of the
transcription factor bcl6 with tbet, gata3, and foxp3 combined
by CD4þ naive T helper cells before stimulation (day 0) and
sorted viable CD3þCD4þ T cells after stimulation (day 5) in the
presence or absence of TAC (1 ng/mL) or SRL (1 ng/mL). The
data show the effect TAC on the polarization of Tfh cells in favor
of Th1 cells. (n¼ 5) Note. Different conditions were compared us-
ing Mann-Whitney testing. SRL, sirolimus; TAC, tacrolimus; Tfh,
T follicular helper; Th1, type 1 T helper cell. *Indicates P < .01.about the impact of TAC and SRL on Tfh cell differentia-
tion and their beneﬁt to B cells in vivo.
In this study, we reported the effect of TAC and SRL on
Tfh-like cell generation using an in vitro co-culture model
[27]. Isolated pure naive human CD4þ T cells were stimu-
lated with anti-CD3/28, IL-12, and IL-21 in the presence of
different concentrations of TAC or SRL. The Tfh-like cells
generated in vitro were studied for their frequency,
phenotype, and capacity to help alloantigen-activated
B cells.MATERIAL AND METHODS
Polarization of Tfh-Like Cells
Peripheral blood of 7 healthy controls was collected according to
the biobank protocol, which was approved by the Medical Ethical
Committee of the Erasmus Medical Center, Rotterdam, The
Netherlands (MEC-2010-022). All individuals gave written
informed consent before the start of the study. The work was per-
formed in accordance with the Declaration of Helsinki.
Peripheral blood mononuclear cells (PBMCs) were isolated us-
ing Ficoll-Paque (VWR, Amsterdam, the Netherlands). Naive
CD4þ T cells were isolated using the CD4þ Naive T-Cell Isolation
Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) in combination
with an AutoMacs (Miltenyi Biotec). Purity of the isolated popu-
lation was determined by ﬂow cytometry by staining with CD4-FITC
(BD Biosciences, Vianen, the Netherlands) and CD45RA-BV421
(Biolegend, London, United Kingdom) and was > 95% for all
samples.
Isolated naive CD4þ T cells were stimulated with a cocktail
consisting of anti-CD3 antibody (2 mg/mL; BD Biosciences), anti-
CD28 antibody (2 mg/mL) (BD Biosciences), goat antimouse
antibody (2 mg/mL) (BD Biosciences), IL-21 (20 ng/mL; R&D
systems, Abingdon, United Kingdom), and IL-12 (20 ng/mL;
PeproTech, London, United Kingdom) in a 96-well plate at
100,000 CD4þ T cells per well for 5 days [27]. This stimulation
was performed in Roswell Park Memorial Institute (RPMI) 1640
medium supplemented with 10% fetal bovine serum (FBS) in the
presence of different concentrations of TAC (0, 0.5, 1, 5, 10, and
20 ng/mL) or SRL (rapamycin) (0, 1, 2, 5, and 10 ng/mL) diluted
in culture medium. After 5 days, the stimulated T cells were
harvested and stained for CD3-BV510 (BioLegend), CD4-FITC
(BD Biosciences), CXCR5-AF647 (BD Biosciences), ICOS-PE-
Fig 6. Effect of TAC and SRL on Tfh cell differentiation. Flow cytometry plots of the differentiation into (A) CXCR5þicosþ and (B)
CXCR5þ pd1þ Tfh cells in the presence of TAC (1 ng/mL) and SRL (1 ng/mL). (C) The percentage of CXCR5þ Tfh cells in the presence
of different concentrations of TAC (0.5, 1, 5, 10, 20 ng/mL) and SRL (1, 2, 5, 10 ng/mL). The right graph shows the normalized data, as
compared to no inhibition. (D) The percentage of CXCR5þicosþ Tfh cells. (E) The percentage of CXCR5þ pd1þ Tfh cells. Note. Data are
presented as the median of the percentage and error bars show interquartile range. Kruskal-Wallis testing was used. icos, inducible
T-cell costimulator; pd1, immunoinhibitory receptor programmed death 1; SRL, sirolimus; TAC, tacrolimus; Tfh, T follicular helper.
*Indicates P < .05.
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Fig 7. Effect of TAC and SRL on icos and pd1expression on CD4þCXCR5þ T cells. (A) The percentage of icosþhi/CD4þCXCR5þ T cells
in the presence of different concentrations of TAC (0.5, 1, 5, 10, 20 ng/mL) and SRL (1, 2, 5, 10 ng/mL) (B) pd1þhi/CD4þCXCR5þ in the
presence of different concentrations of TAC (0.5, 1, 5, 10, 20 ng/mL) and SRL (1, 2, 5, 10 ng/mL). Note. Each dot represents one sample.
Data are presented as the median of the percentage and error bars show interquartile range. Kruskal-Wallis testing was used. icos,
inducible T-cell costimulator; pd1, immunoinhibitory programmed death protein 1; SRL, sirolimus; TAC, tacrolimus. *Indicates P <
.05. yIndicates P < .01.
6 KRAAIJEVELD, LI, YAN ET ALCy7 (BioLegend), PD1-APC-Cy7 (BioLegend), CD45ROeBV421
(BioLegend), and 7-AAD ViaProbe (BD Biosciences) for 30
minutes at room temperature and measured on a ﬂuorescence-
activated cell sorting (FACS) Canto 2 (BD Biosciences).
We repeated this experimental setup (n ¼ 5) to determine
mRNA expression of IL-21 and the transcription factors of 5
different T helper subsets, that is, tbet (Th1), gata3 (Th2), foxp3
(Treg), rorgt (Th17), and bcl6 (Tfh). The stimulation was per-
formed as described above in the presence or absence of 1 ng/mL
TAC or 1 ng/mL SRL. Next, we stained these stimulated cells for
CD3-BV510 (BioLegend), CD4-BV421(BioLegend), CXCR5-
AF647 (BD Biosciences), PD1-APC-Cy7 (BioLegend),
CD45RO-PE-Cy7 (BD Biosciences), and 7AAD ViaProbe (BD
Biosciences) for 30 minutes. Viable CD3þCD4þ T cells were
isolated with FACSAria II (BD Biosciences). RNA was isolated
with the RNeasy Micro Kit (Qiagen, Hilden, Germany) for the
collection of high-quality RNA. Total RNA was subsequently
reverse transcribed with oligo-deoxythymine primer. We studied
mRNA expression levels by quantitative reverse transcriptase
polymerase chain reaction (RT-qPCR) using the following PCR
primers: IL-21 (HS 00222327-M1), bcl6 (HS 00153368-M1), tbet
(HS 00894392-M1), foxp3 (HS 00203958-M1), rorgt (HS
00172858-M1), and gata3 (HS 00231122-M1) (ThermoFisher
Scientiﬁc, Waltham, Mass, United States). The expression level of
each target gene was quantiﬁed by measuring the threshold cycle
(Ct). This was then transformed on a TaqMan Real-Time PCR
system (ThermoFisher Scientiﬁc) to the number of cDNA copies
(2(40-Ct)) (When the threshold is exceeded, every cycle before the
last cycle of 40 means a doubling of the amount of copies) and
their relative concentrations were normalized to relativeconcentrations of 18S (HS 99999901-S1) the housekeeping gene
present in each sample. [28]
T- and B-Cell Interaction Assays
The B-cell activating properties of the induced Tfh-like cells after
Tfh polarization conditions were studied in co-culture experiments
with isolated B cells [8,29]. B cells were isolated by depletion of
CD43þ cells by using a CD43 isolation kit in combination with an
AutoMacs (Miltenyi Biotec) Afterwards the cells were labeled with
CellTrace CFSE (Invitrogen, Paisley, United Kingdom). B cells
(50,000 per well) were co-cultured for 7 days with induced Tfh-like
cells (25,000 per well) in a 96-well plate in the presence of 50,000
irradiated (40 Gy) allogeneic PBMCs [11] PBMCs from which the B
cells were depleted (CD19 isolation kit in combination with Auto-
Macs) [11] in RPMI-1640 with 10% FBS. At day 7 the cells were
harvested and stained with 7AAD ViaProbe (BD Biosciences),
CD4-PerCP (BD Biosciences), CD19-BV510 (Biolegend), CD27-
PE-Cy7 (BD Biosciences), CD38-BV421 (BD Biosciences), IgM-
PE (BD Biosciences), IgD-APC-Cy7 (BioLegend), and measured
using a FACSCanto II (BD Biosciences) ﬂow cytometer. A ﬂow
chart summarizing the experimental setup can be found in Fig 1.
Data Analyses
All ﬂow cytometry results were analyzed using Kaluza Software
version 1.5 (Beckman Coulter, Woerden, the Netherlands). Statis-
tical analyses were performed using GraphPad Prism, software
version 5.0.1 (GraphPad Software Inc, San Diego, Calif, United
States). Mann-Whitney testing was used to determine signiﬁcant
differences in relative mRNA expression. Kruskal-Wallis testing
TACROLIMUS AND SIROLIMUS INHIBIT TFH GENERATION 7was used to compare the changes under the 2 drug treatments with
different concentrations in the Tfh differentiation experiments.
Wilcoxon signed-rank testing was used to determine signiﬁcant
differences in the T- and B-cell co-culture experiments. P values less
than .05 were considered signiﬁcantly different.
RESULTS
In Vitro Differentiation of Naive T Cells
CD4þ naive T cells were stimulated with anti-CD3/CD28
antibodies, goat antimouse antibody, IL-21, and IL-12 for
5 days (Fig 1). Next, the viable CD3þ CD4þ T cells were
isolated. In these isolated samples the expression of the
different transcription factors was measured. After stimu-
lation, mRNA levels of bcl6, tbet, foxp3, and gata3 were
increased (Fig 2). In this culture system no positive signal
was found for rorgt.
Fig 3 depicts the gating strategy of unstimulated CD4þ
(naive) T cells (Fig 3A) and their differentiation into Tfh-
like cells after a 5-day stimulation (Fig 3B). After stimula-
tion, a substantial proportion of the naive T cells differen-
tiated into CD4þCXCR5þ T cells. These cells also express
CD45RO (for memory T cells), and the costimulatory
markers pd1and icos (Fig 4).
Effect of TAC and SRL on T-Cell Differentiation
The effect of TACand SRLon the expression of transcription
factor bcl6 within the Tfh-like cells was examined on sortedand stimulatedCD3þCD4þT cells (Fig 5).Of interest are our
ﬁndings that in the presence of subtherapeutic concentra-
tions of TAC (1 ng/mL) and SRL (1ng/mL). Of the residual,
low number of SRL and TACnonsensitive T cells the balance
between bcl6 and the other noneTfh cell transcription factors
was studied. In the T cells, a shifted balance toward a higher
proportion of bcl6 mRNA was found in both the TAC and
SRL experiments (Fig 5). Next, we deﬁned the effect of TAC
and SRL on CD4þCXCR5þ T cells. Typical examples of
these Tfh-like cells in the presence or absence of TAC and
SRL are shown in Fig 6A and 6B. Within the CD4þ T cells
29% (median; range 16%-43%) were CXCR5þ cells (Fig
6C), 27% (15%-42%) of these CD4þ T cells expressed both
CXCR5 and pd1 cells, and 24% (15%-44%) of the CD4þ T
cells expressed both CXCR5 and icos (Fig 6D). Due to the
low yields of CD4þ naive T cells after isolation, not all of the
conditions have been met for a number of samples. In the
presence of both TAC and SRL, even at subtherapeutic doses
of 1 ng/mL, the differentiation of naive T cells toward
CD4þCXCR5þ, CD4þCXCR5þicosþ and CD4þCXCR5þ
pd1þ T cells was inhibited by > 90% (Fig 6DeE). The
expression of pd1 and icos was reduced within the residual
CD4þCXCR5þ T cells (both P < .05; Fig 7).
TAC and SRL Inhibit Tfh-Like Cell Help to B Cells
A typical example of B-cell proliferation and differentiation
is shown in Fig 8. After allogeneic stimulation, the TFig 8. Analysis of B cells after co-culture
with induced Tfh cells and alloantigen for
7 days. This ﬁgure shows representative
FACS plots with an example of the gating
strategy used to identify the frequency of
plasmablasts, class-switched B cells,
transitional B cells, and the level of B-
cell proliferation. FACS, ﬂuorescence-
activated cell sorting; Tfh, T follicular
helper.
Fig 9. Differentiation of B cells into different subsets. Functional effect of the induced follicular helperelike cells on the activation and
differentiation of B cells when generated in the absence and presence of TAC (1 ng/mL) and SRL (1 ng/mL). (A) The frequency of prolif-
erating B cells. (B) A typical example of the proliferation of the 3 different stimulation conditions is depicted. (C) The frequency of plas-
mablasts. (D) The frequency of class-switched B cells. (E) The frequency of transitional B cells. Tfh cells generated from naive CD4þ T
cells and resting B cells were obtained from 7 healthy controls. Note. The median is shown. Wilcoxon matched pairs test was used.
SRL, sirolimus; TAC, tacrolimus; Tfh, T follicular helper. yIndicates P < .01.
8 KRAAIJEVELD, LI, YAN ET ALcellemediated B-cell proliferation and differentiation to-
ward transitional B cells, class-switched B cells, and plas-
mablasts was determined. In the presence of alloantigen, a
substantial proportion of B cells proliferated (20.5%) and
differentiated into plasmablasts (median: 4.8%).
We found that T-cell help function was impaired when
induced in the presence of TAC or SRL (Fig 9). T cells
including Tfh-like cells generated in the absence of any
immunosuppression nicely demonstrated the help they
provided to B cells, which proliferated and differentiated
into diverse B cell subsets. In contrast, Tfh-like cells
generated in the presence of TAC or SRL could not activate
B cells effectively. Decreased proliferation and differentia-
tion into both transitional B cells and plasmablasts were
found, while the frequency of class-switched B cells was
unaffected. SRL inhibited B-cell proliferation by 60%
(median) and TAC by 38% (both P < .01) (Fig. 9A). In Fig
10A we depicted the mRNA expression level of IL-21 after
Tfh-like cell differentiation measured in samples generated
in the absence and presence of TAC and SRL. The lower
graph (Fig 10B) depicts the normalized data. In the
immunosuppressed samples we found lower levels of IL-21
mRNA expression. These data suggest that the impaired T
celledependent B cell help might also be the result of lowerIL-21 production by these TAC and SRL Tfh-like generated
cells.DISCUSSION
We used an in vitro co-culture model to study Tfh-
dependent B-cell activation in the presence of TAC or
SRL. We found that TAC and SRL inhibited the generation
of human Tfh-like cells (CD4þCXCR5þicosþ and
CD4þCXCR5þ pd1þ) by 90% to 95% at therapeutic or
even lower concentrations. We presume that in this in vitro
system, the effect of these immunosuppressive drugs are
more profound than in vivo, because these drugs are not
able to be caught up in another compartment (eg, red blood
cells will capture a great part of TAC in vivo). In this study,
in the remaining T cells, the balance shifted toward bcl6.
Tfh cells have been reported to be regulated by multiple
signals [30,31]. Research reports have demonstrated that
the icos-PI3K/Akt/mtor signaling pathway plays a critical role
in promoting Tfh cell differentiation [32e34]. Both mtor
complex 1 and mtor complex 2 contribute to Tfh cell dif-
ferentiation via different mechanisms. Mtor complex 1
mainly promotes proliferation of CD4þ T cells to achieve
the required division for Tfh cell differentiation, while mtor
Fig 10. IL-21 mRNA expression. In this ﬁgure, the effect of TAC
and SRL on the relative mRNA expression of IL-21 of pure FACS-
sorted CD3þCD4þ T cells is depicted. The relative mRNA expres-
sion of IL-21 after of stimulation with anti-CD3/28, IL-12, and
IL-21 in the presence or absence of TAC or SRL is shown in
the top ﬁgure. Normalized data (Stim ¼ set as 100%) is depicted
within the lower ﬁgure. Note. Mann-Whitney testing was used.
FACS, ﬂuorescence-activated cell sorting; IL, interleukin; SRL,
sirolimus; TAC, tacrolimus. yIndicates P < .01.
TACROLIMUS AND SIROLIMUS INHIBIT TFH GENERATION 9complex 2 assists Tfh cell differentiation by activating Akt
and tcf1 [35,36]. Furthermore, it is well established that SRL
promotes the generation of regulatory T cells [37,38], which
was recently reported to play an important role in control-
ling the expansion of Tfh cell numbers[39]. This explains
why in the presence of SRL the generation of Tfh cells was
inhibited. However, the few T cells that escape from mtor
inhibition by SRL can have a Tfh-like proﬁle. Despite the
inhibition of this Tfh-like cell subtype, we found that in the
presence of TAC, the transcription factor bcl6 was abun-
dantly present in these cells. Although this ﬁnding is in line
with observations from previous study in TAC-treated pa-
tients [40], mRNA levels and cell numbers cannot be
directly translated to cellular functions. Despite the high
presence of bcl6, lower mRNA expression of IL-21 was
found, and fewer Tfh cells were generated when in the
presence of this agent [20,41], which is most likely the result
of less T-cell activation and proliferation. Where our pre-
vious studies showed that SRL has a more potent effect on
inhibition of Tfh differentiation, in this in vitro study wewere unable to ﬁnd a signiﬁcant difference between these 2
immunosuppressive drugs. This can be attributed to a dif-
ference in results between in vivo and in vitro studies as well
as that the TAC- and SRL-treated patients in the former
in vivo study are also given other immunosuppressive drugs
[26].
Ballesteros-Tato et al [42] and Johnston et al [43] both
reported that IL-2 was a negative regulator of Tfh cell dif-
ferentiation via a stat5/blimp1edependent mechanism, which
then inhibited the B-cell response in vivo. When IL-2 is
scarce, subsequent Tfh cell differentiation may be
enhanced, ultimately reinforcing the humoral response [44].
However, this differentiation did not result in direct B-cell
help as these T cells had a lower capacity to provide B-cell
help [20,41].
Apart from IL-2 production, TAC also prevents the in-
duction of other cytokines. These soluble mediators, for
example, IL-6 and IL-21, deliver signals through stat3-
mediated pathways and are critical for the expansion and
function of Tfh cells [45]. Thus, even in the presence of
in vitro added IL-12, IL-21, and T-cell receptor activation by
anti-CD3/28 antibodies, TAC still inhibited Tfh
differentiation.Study Limitations
This study has some limitations. This study was performed
on a limited PBMC samples from volunteers without a
signiﬁcant medical history (n ¼ 4 to n ¼ 7). Therefore, these
ﬁndings must be considered as preliminary data. Secondly,
our study showed that only a minute population still
differentiated toward Tfh-like cells. To study the functional
properties of these few cells, isolation of the cells is
required. These cells should then be co-cultured with B cells
in the same way as currently described. But since the
inhibitory effect of TAC and SRL both interfere with T-cell
proliferation and differentiation, we found that isolation of
these cells was practically impossible. Despite this limita-
tion, we can conclude that the direct effect TAC and SRL
has on Tfh differentiation still affects B-cell proliferation
and differentiation in an indirect manner. This is of rele-
vance because in vivo, in immunosuppressed transplant
patients, the number of Tfh cells that escape from TAC,
SRL, or other immunosuppressive treatments may still
provide help to B cells. For example, after T-cell depletion
therapy, which triggers homeostatic T-cell proliferation [46]
in patients with kidney transplant, an association was found
between the risk of developing ABMR and the frequency of
Tfh cells in the circulation [40,47].
Where this study solely focused on the differentiation of
Tfh-like cells originating from a naive T helper subtype, the
effect of these immunosuppressive drugs or depletion
therapy by anti-thymoglobulin on memory Tfh-like cells was
not tested and is therefore an interesting and relevant
subject for future studies. In addition, other immune cell
populations, such as follicular natural killer T cells, can
trigger B-cell responses [48].
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In conclusion, in vitro generated human Tfh-like cells pro-
vide the required signals to help B cells. Immunosuppres-
sion, in our case TAC and SRL, affects this process by
halting the differentiation into Tfh-like cells, effectively
canceling their ability to activate B cells. These ﬁndings
suggest that in patients with a history of transplant, immu-
nosuppressive drugs may similarly inﬂuence both the dif-
ferentiation and function of Tfh cells.REFERENCES
[1] Sellarés J, De Freitas DG, Mengel M, Reeve J, Einecke G,
Sis B, et al. Understanding the causes of kidney transplant failure:
The dominant role of antibody-mediated rejection and non-
adherence. Am J Transplant 2012;12:388e99.
[2] Einecke G, Sis B, Reeve J, Mengel M, Campbell PM,
Hidalgo LG, et al. Antibody-mediated microcirculation injury is the
major cause of late kidney transplant failure. Am J Transplant
2009;9:2520e31.
[3] Inaba A, Clatworthy MR. Novel immunotherapeutic strate-
gies to target alloantibody-producing B and plasma cells in trans-
plantation. Curr Opin Organ Transplant 2016;21:419e26.
[4] de Leur K, Clahsen-van Groningen MC, van den Bosch TPP,
de Graav GN, Hesselink DA, Samsom JN, et al. Characterization of
ectopic lymphoid structures in different types of acute renal allo-
graft rejection. Clin Exp Immunol 2018;192:224e32.
[5] Baan CC, de Graav GN, Boer K. T follicular helper cells in
transplantation: the target to attenuate antibody-mediated alloge-
neic responses? Curr Transplant Rep 2014;1:166e72.
[6] Kwun J, Manook M, Page E, Burghuber C, Hong J,
Knechtle SJ. Crosstalk between T and B cells in the germinal center
after transplantation. Transplantation 2017;101:704e12.
[7] Byford ET, Carr M, Ladikou E, Ahearne MJ, Wagner SD.
Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are
elevated in low-grade B-cell non-Hodgkin's lymphoma and cTfh
gene expression is perturbed in marginal zone lymphoma. PLoS
One 2018;13:e0190468.
[8] Shabir S, Girdlestone J, Briggs D, Kaul B, Smith H, Daga S,
et al. Transitional B lymphocytes are associated with protection
from kidney allograft rejection: a prospective study. Am J Trans-
plant 2015;15:1384e91.
[9] Luk F, Carreras-Planella L, Korevaar SS, de Witte SFH,
Borràs FE, Betjes MGH, et al. Inﬂammatory conditions dictate the
effect of mesenchymal stem or stromal cells on B cell function.
Front Immunol 2017;8:1042.
[10] Morita R, Schmitt N, Bentebibel SE, Ranganathan R,
Bourdery L, Zurawski G, et al. Human blood CXCR5þCD4þT cells
are counterparts of T follicular cells and contain speciﬁc subsets
that differentially support antibody secretion. Immunity 2011;34:
108e21.
[11] de Leur K, Dor FJMF, Dieterich M, van der Laan LJW,
Hendriks RW, Baan CC. IL-21 receptor antagonist inhibits differ-
entiation of B cells toward plasmablasts upon alloantigen stimula-
tion. Front Immunol 2017;8:1e10.
[12] de Graav GN, Dieterich M, Hesselink DA, Boer K, Clah-
sen-van Groningen MC, Kraaijeveld R, et al. Follicular T helper
cells and humoral reactivity in kidney transplant patients. Clin Exp
Immunol 2015;180:329e40.
[13] Yan L, de Leur K, Hendriks RW, van der Laan LJW, Shi Y,
Wang L, et al. T Follicular helper cells as a new target for immu-
nosuppressive therapies. Front Immunol 2017;8:1e11.
[14] Vinuesa CG, Cyster JG. How T cells earn the follicular rite
of passage. Immunity 2011;35:671e80.
[15] Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG,
Bevan MJ, Rao A. Interleukin-2 and inﬂammation induce distincttranscriptional programs that promote the differentiation of
effector cytolytic T cells. Immunity 2010;32:79e90.
[16] Gong D, Malek TR. Cytokine-dependent blimp-1 expres-
sion in activated T cells inhibits IL-2 production. J Immunol
2007;178:242e52.
[17] Nurieva RI, Podd A, Chen Y, Alekseev AM, Yu M, Qi X,
et al. STAT5 protein negatively regulates T follicular helper (Tfh)
cell generation and function. J Biol Chem 2012;287:11234e9.
[18] Kannegieter NM, Hesselink DA, Dieterich M,
Kraaijeveld R, Rowshani AT, Leenen PJM, et al. The effect of
tacrolimus and mycophenolic acid on CD14þ monocyte activation
and function. PLoS One 2017;12:1e9.
[19] Vafadari R, Kraaijeveld R, Weimar W, Baan CC. Tacroli-
mus inhibits NF-kB activation in peripheral human T cells. PLoS
One 2013;8:e60784.
[20] Taylor AL, Watson CJE, Bradley JA. Immunosuppressive
agents in solid organ transplantation: mechanisms of action and
therapeutic efﬁcacy. Crit Rev Oncol Hematol 2005;56:23e46.
[21] Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE,
Proneth A, Duvoux C, et al. Sirolimus use in liver transplant re-
cipients with hepatocellular carcinoma. Transplantation 2016;100:
116e25.
[22] Spolski R, Gromer D, Leonard WJ. The g c family of cy-
tokines: ﬁne-tuning signals from IL-2 and IL-21 in the regulation of
the immune response. F1000Res 2017;6:1872.
[23] Heidt S, Roelen DL, Eijsink C, Van Kooten C, Claas FHJ,
Mulder A. Effects of immunosuppressive drugs on puriﬁed human b
cells: evidence supporting the use of MMFand rapamycin. Trans-
plantation 2008;86:1292e300.
[24] Heidt S, Roelen DL, Eijsink C, Eikmans M, Van Kooten C,
Claas FHJ, et al. Calcineurin inhibitors affect B cell antibody re-
sponses indirectly by interfering with T cell help. Clin Exp Immunol
2010;159:199e207.
[25] De Graav GN, Hesselink DA, Dieterich M, Kraaijeveld R,
Verschoor W, Roelen DL, et al. Belatacept does not inhibit
follicular T cell-dependent B-cell differentiation in kidney trans-
plantation. Front Immunol 2017;8:1e16.
[26] Traitanon O, Mathew JM, Monica G La, Xu L, Mas V,
Gallon L. Differential effects of tacrolimus versus sirolimus on the
proliferation, activation and differentiation of human B cells. PLoS
One 2015;10:1e15.
[27] Achour A, Simon Q, Mohr A, Séité JF, Youinou P,
Bendaoud B, et al. Human regulatory B cells control the TFH cell
response. J Allergy Clin Immunol 2017;140:215e22.
[28] van Besouw NM, Caliskan K, Peeters AM, Klepper M,
Dieterich M, Maat LP, et al. Interleukin-17-producing CD4(þ)
cells home to the graft early after human heart transplantation.
J Heart Lung Transplant 2015;34:933e40.
[29] Franquesa M, Mensah FK, Huizinga R, Strini T, Boon L,
Lombardo E, et al. Human adipose tissue-derived mesenchymal
stem cells abrogate plasmablast formation and induce regulatory B
cells independently of T helper cells. Stem Cells 2015;33:880e91.
[30] Tangye SG, Ma CS, Brink R, Deenick EK. The good, the
bad and the ugly d TFH cells in human health and disease. Nat Rev
Immunol 2013;13:412e26.
[31] Fourtounas C, Dousdampanis P, Sakellaraki P, Rodi M,
Georgakopoulos T, Vlachojannis JG, et al. Different immunosup-
pressive combinations on T-cell regulation in renal transplant re-
cipients. Am J Nephrol 2010;32:1e9.
[32] Gigoux M, Lovato A, Leconte J, Leung J, Sonenberg N,
Suh WK. Inducible costimulator facilitates T-dependent B cell
activation by augmenting IL-4 translation. Mol Immunol 2014;59:
46e54.
[33] Gigoux M, Shang J, Pak Y, Xu M, Choe J, Mak TW, et al.
Inducible costimulator promotes helper T-cell differentiation
through phosphoinositide 3-kinase. Proc Natl Acad Sci U S A
2009;106:20371e6.
[34] Rolf J, Bell SE, Kovesdi D, Janas ML, Soond DR,
Webb LMC, et al. Phosphoinositide 3-kinase activity in T cells
TACROLIMUS AND SIROLIMUS INHIBIT TFH GENERATION 11regulates the magnitude of the germinal center reaction. J Immunol
2010:1854042e52.
[35] Yang J, Lin X, Pan Y, Wang J, Chen P, Huang H, et al.
Critical roles of mTOR complex 1 and 2 for t follicular helper cell
differentiation and germinal center responses. Elife 2016;5:1e22.
[36] Zeng H, Cohen S, Guy C, Shrestha S, Neale G, Brown SA,
et al. mTORC1 and mTORC2 kinase signaling and glucose meta-
bolism drive follicular helper T cell differentiation. Immunity
2016;45:540e54.
[37] Li Y, Shi Y, Liao Y, Yan L, Zhang Q, Wang L. Differential
regulation of Tregs and Th17/Th1 cells by a sirolimus-based
regimen might be dependent on STAT-signaling in renal trans-
plant recipients. Int Immunopharmacol 2015;28:435e43.
[38] Kang J, Huddleston SJ, Fraser JM, Khoruts A. De novo
induction of antigen-speciﬁc CD4þCD25þFoxp3þ regulatory T cells
in vivo following systemic antigen administration accompanied by
blockade of mTOR. J Leukoc Biol 2008;83:1230e9.
[39] Wing JB, Ise W, Kurosaki T, Sakaguchi S. Regulatory T
cells control antigen-speciﬁc expansion of Tfh cell number and
humoral immune responses via the coreceptor CTLA-4. Immunity
2014;41:1013e25.
[40] Li YM, Li Y, Shi YY, Yan L, Wu XJ, Tang JT, et al. Impact
of immunosuppressive drugs on circulating Tfh cells in kidney
transplant recipients: a pilot study. Transpl Immunol 2018;46:1e7.
[41] O’Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O’Neill EA.
FK-506- and CsA-sensitive activation of the interleukin-2 promoter
by calcineurin. Nature 1992;357:692.[42] Ballesteros-Tato A, León B, Graf BA, Moquin A,
Adams PS, Lund FE, et al. Interleukin-2 inhibits germinal center
formation by limiting T follicular helper cell differentiation. Im-
munity 2012;36:847e56.
[43] Johnston RJ, Choi YS, Diamond JA, Yang JA, Crotty S.
STAT5 is a potent negative regulator of T FH cell differentiation.
J Exp Med 2012;209:243e50.
[44] León B, Bradley JE, Lund FE, Randall TD, Ballesteros-
Tato A. FoxP3(þ) regulatory T cells promote inﬂuenza-speciﬁc Tfh
responses by controlling IL-2 availability. Nat Commun 2014;5:
3495.
[45] Ma CS, Suryani S, Avery TD, Chan A, Nanan R, Santner-
Nanan B, et al. Early commitment of naive human CD4þ T cells to
the T follicular helper (TFH) cell lineage is induced by IL-12.
Immunol Cell Biol 2009;87:590e600.
[46] Bouvy AP, Kho MM, Klepper M, Litjens NH, Betjes MG,
Weimar W, et al. Kinetics of homeostatic proliferation and thy-
mopoiesis after rATG induction therapy in kidney transplant pa-
tients. Transplantation 2013;96:904e13.
[47] Knechtle SJ, Pirsch JD, H Fechner J Jr, Becker BN,
Friedl A, Colvin RB, et al. Campath-1H induction plus rapamycin
monotherapy for renal transplantation: results of a pilot study. Am
J Transplant 2003;3:722e30.
[48] Tonti E, Fedeli M, Napolitano A, Iannacone M, von
Andrian UH, Guidotti LG, et al. Follicular helper NKT cells induce
limited B cell responses and germinal center formation in the
absence of CD4(þ) T cell help. J Immunol 2012;188:3217e22.
